Sponsor:  Ohio ENT & Allergy Physicians Do any of these symptoms sound familiar: Stuff or Runny Nose? Headaches? Sinus ...

After pathology and CT review ... viewarticle/408749 Endoscopic view of left nasal cavity showing polyposis in middle meatus. Notice how the polyps exhibit a glistening, almost translucent ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

These quiz questions about nasal polyps (NP) are derived from recent literature. Are you up to date? At the end of the quiz, compare your score with those of your physician colleagues. Links to ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

Nasal polyps may also be treated by injecting corticosteroids directly into the polyp itself. It's believed that in steroid ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Dr. Albritton is a resident physician and Dr. Kingdom is Assistant Professor in the Department of Otolaryngology at Emory University School of Medicine, Atlanta, Ga. Albritton FD, Kingdom TT.

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.